The administration has, thus far, taken measured action against drug prices since President Trump announced his “blueprint” to tackle high drug prices in May. Several companies have made promises to work on lowering prices, but other than that, progress has been slow. As of late, though, further-reaching measures involving Medicare, pharmacy benefit managers, and a deregulatory framework may finally be taking shape . . .

To read more, sign up for aFree 30-Day Trial   of MRP's research, orLog In